Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 48Arthralgia 3Advanced Breast Cancer 3Polycystic Ovary Syndrome 2Osteoporosis 2Fractures, Bone 2Carcinoma, Intraductal, Noninfiltrating 2Breast Diseases 2Breast Cancer Female 2Sexuality 1Sexual Dysfunctions, Psychological 1Neurotoxicity Syndromes 1Neoplasm Metastasis 1Luminal B/HER2-negative Breast Cancer 1Leiomyoma 1Infertility 1Hormone-receptor-positive Breast Cancer 1Hormone Receptor Positive Breast Carcinoma 1Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer 1HR+/HER2- Early Breast Cancer 1HR+/HER2+ Early Breast Cancer 1Fatigue 1Estrogen Receptor and/or Progesterone Receptor Positive 1Endometrial Stromal Tumors 1Endometrial Neoplasms 1Bulbo-Spinal Atrophy, X-Linked 1Breast Carcinoma In Situ 1Breast Cancer Metastatic 1Bone Diseases, Metabolic 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Toremifene 1Tamoxifen 1Ovariectomy 1Gonadotropin-Releasing Hormone 1Aromatase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hormone-receptor-positive Breast Cancer × Aromatase Inhibitors × Clear all
NCT05801705 2023-05-18

Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Unknown
700 enrolled
Breast

Hormone-receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡